Document is current
Any future updates will be listed below
-
Authors
Feldmeier, Gregor https://orcid.org/0000-0001-7420-5752
Löffler, Christin
Altiner, Attila
Wollny, Anja
von Podewils, Felix
Ritzke, Manuela
-
Funding
Funding for this research was provided by:
Ministry of Economics of Mecklenburg-Vorpommern, Germany
Universität Rostock
- License Information
-
More Information
Article History
Received: 15 December 2021
Accepted: 14 September 2022
First Online: 21 September 2022
Declarations
:
: Ethical approval was obtained from the Ethics committee at Rostock University Medical Center (Ref: A2018-0143) in 2018. All participants involved provided written informed consent.
: Not applicable.
: The authors declare that they have no competing interests. FvP is on the speaker’s bureau of Bial, Desitin Arzneimittel, Eisai, GW Pharmaceutical companies, Arvelle Therapeutics, Angelinipharma, Zogenix, and UCB Pharma and reports personal fees and grants from Bial, Desitin Arzneimittel, Eisai GmbH, GW Pharmaceutical companies, Arvelle Therapeutics, Angelinipharma, Zogenix, and UCB Pharma.
